US Patent

US10517868 — Methods and compositions for treating diabetes, metabolic syndrome and other conditions

Method of Use · Assigned to Strongbridge Dublin Ltd · Expires 2026-01-10 · 0y expired

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and compositions for treating type 2 diabetes, hyperglycemia, and other conditions using a specific ketoconazole enantiomer.

USPTO Abstract

Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3283 — Recorlev

Patent Metadata

Patent number
US10517868
Jurisdiction
US
Classification
Method of Use
Expires
2026-01-10
Drug substance claim
No
Drug product claim
No
Assignee
Strongbridge Dublin Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.